Intersect ENT Inc (XENT) CFO Jeryl L. Hilleman Sells 12,833 Shares
Intersect ENT Inc (NASDAQ:XENT) CFO Jeryl L. Hilleman sold 12,833 shares of the business’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $30.06, for a total value of $385,759.98. Following the completion of the sale, the chief financial officer now directly owns 27,833 shares of the company’s stock, valued at $836,659.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of Intersect ENT Inc (XENT) traded down $0.95 during midday trading on Tuesday, hitting $28.80. The stock had a trading volume of 333,431 shares, compared to its average volume of 291,532. Intersect ENT Inc has a fifty-two week low of $9.25 and a fifty-two week high of $33.25.
Intersect ENT (NASDAQ:XENT) last released its earnings results on Thursday, November 2nd. The medical equipment provider reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.05. The firm had revenue of $22.31 million during the quarter, compared to the consensus estimate of $21.53 million. Intersect ENT had a negative return on equity of 15.96% and a negative net margin of 19.81%. The firm’s revenue for the quarter was up 20.8% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.22) earnings per share. research analysts anticipate that Intersect ENT Inc will post -0.63 EPS for the current year.
Several analysts recently weighed in on the company. BTIG Research reissued a “hold” rating on shares of Intersect ENT in a report on Tuesday, November 7th. Northland Securities reaffirmed a “hold” rating and set a $25.00 target price on shares of Intersect ENT in a report on Friday, November 3rd. Zacks Investment Research lowered Intersect ENT from a “buy” rating to a “hold” rating in a report on Wednesday, November 1st. Canaccord Genuity upped their target price on Intersect ENT from $32.00 to $37.00 and gave the company a “buy” rating in a report on Wednesday, September 13th. Finally, Bank of America upped their target price on Intersect ENT from $33.00 to $40.00 and gave the company a “buy” rating in a report on Monday, September 11th. Five equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $30.88.
About Intersect ENT
Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.
Receive News & Ratings for Intersect ENT Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT Inc and related companies with MarketBeat.com's FREE daily email newsletter.